Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Nemesis01on Dec 17, 2019 2:05pm

226 Views

Post# 30464662

Wizard Lake Asset Swap

Not a fan of this deal. Too many "subject to"s with what is essentially an earn out agreement.

I would have more faith if Whitebark was a player in Aussie Oil and Gas but they are worse off than Point Loma with over 2 billion shares outstanding on a market cap of $30m. I'm not sure Whitebark can raise funds to cover their "subject to"s.

At least PLX is getting a short term cash injection.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario